Lenz Therapeutics reported successful results from a late-stage study testing experimental drugs for near vision loss, leading to a nearly 23% increase in its shares. The lead product candidate, LNZ100, showed significant improvement in patients’ ability to see details at a distance of 20 feet three hours after treatment. The other drug, LNZ101, also demonstrated positive results but did not outperform LNZ100. The San Diego-based company plans to submit a marketing application for LNZ100 in the US by mid-2024.
Source link
Lenz Therapeutics’ Eye Disease Drugs Meet Main Goal Of Late-stage Study
